Cancer Clinical Trials

The Koontz Center is currently enrolling patients in the following trials specifically targeting advanced breast cancer.

• A011502 Aspirin in Preventing Recurrence of Cancer in Patients with Her2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery and/or Radiation Therapy
  Learn more
• Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
  Learn more
• A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
  Learn more
• Novartis - Ribociclib with endocrine therapy in the adjuvant tx of HR-positive, Her2 negative early breast cancer (NATALEE) (Mel / Kelley)
  Learn more
• SGNTUC-025-A single arm, open label phase 2 study of tucatinib in combination with trastuzumab deruxtecan in subjects with previously treated unresectable locally-advanced or metastatic Her2+ breast cancer
  Learn more
• EFC15935 A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER+, HER2- breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease
  Learn more
• Sermonix ESR1 SMX 18001 An Open, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation
  Learn more
• Sanofi ACT16105 ACT16105: Phase 2 study of SAR439859 vs physician's choice in premenopausal and postmenopausal localled advanced or metastatic ER-positive breast cancer
  Learn more
• H3 Biomedical A101: Phase II multicenter, open-label trial of H3B-6545, a covalent antagonist of estrogen receptor alpha, inwomen with locally advanced or metastatic estrogen receptor-positive, Her2 negative breast cancer
• H3B-6545-G000-102 An Open Label multicenter phase 1b study of H3B-6545 in combination with palbociclib in women with advanced or metastatic estrogen receptor positive Her2 negative breast cancer
  Learn more
• A Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)
  Learn more
• Seattle Genetics SGNTUC-016 Seattle Genetics Phase 3 clinical trial of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally advanced or metastatic HER2+ breast cancer (SGNTUC-016)
  Learn more
• A Compassionate use study of leronlimab (PRO140) plus treatment of physician's choice in patients with CCR5+ metastatic triple-negative breast cancer
  Learn more
• A011401 Breast Cancer Weight Loss Study (BWEL Study): Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
  Learn more
• Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
  Learn more

Learn More

Get to know the Koontz Center for Advanced Breast Cancer: